News Quantified

CSTL – castle biosciences, inc. - common stock (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

The Melanoma Research Foundation Launches its Inaugural Washington DC 5K Fundraiser with a Goal of $115,000 in Support of Melanoma Research, Education and Advocacy

Castle Biosciences inks expansion at Nova Place [Yahoo! Finance]

Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 [TheStreet.com]

Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year

-7.2%

BEAT

21.7%

BEAT

32.8%

BEAT

-10.7%

MISS

Form 4 CASTLE BIOSCIENCES INC For: Apr 06 Filed by: MAETZOLD DEREK J

Form ARS CASTLE BIOSCIENCES INC For: Dec 31

Form DEF 14A CASTLE BIOSCIENCES INC For: May 28

Form DEFA14A CASTLE BIOSCIENCES INC

Form 4 CASTLE BIOSCIENCES INC For: Mar 26 Filed by: MAETZOLD DEREK J

Top News Gainers

11/11 Q3/2019 9/30/2019 EPS 0.050 ZacksConsensus -0.310 ActVsEst 0.360 - Beat 19.6%

3/16 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 18.9%

8/22 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 14.1%

4/6 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference 13.4%

10/29 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting 11.0%

7/31 Form 4 CASTLE BIOSCIENCES INC For: Jul 29 Filed by: Cook Joseph C. III 10.9%

12/19 Form 8-K CASTLE BIOSCIENCES INC For: Dec 13 8.6%

10/31 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk 8.4%

10/29 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%

1/3 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.6%

Top News Decliners

3/11 Castle Biosciences (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $37.00 to $38.00. They now have an "outperform" rating on the stock. -12.7%

10/21 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%

9/6 Castle Biosciences (NASDAQ: CSTL) was given a new $33.00 price target on by analysts at Leerink Swann. They now have a "buy" rating on the stock. -11.5%

3/11 Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call Transcript [The Motley Fool] -11.5%

2/25 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 -9.4%

2/21 Form 4 CASTLE BIOSCIENCES INC For: Feb 19 Filed by: HealthQuest Venture Management, L.L.C. -7.4%

1/13 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -7.0%

9/3 Form 8-K CASTLE BIOSCIENCES INC For: Sep 03 -6.9%

10/18 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node -5.7%

7/29 Form S-8 CASTLE BIOSCIENCES INC -5.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day